ArticleHuman vaccines & immunotherapeutics2014
Engineered PRINT(®) nanoparticles for controlled delivery of antigens and immunostimulants.
Article in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials.Nano today · 2024Article
- Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases.Advanced nanobiomed research · 2021Article
- Injectable, Ribbon-Like Microconfetti Biopolymer Platform for Vaccine Applications.ACS applied materials & interfaces · 2020Article
- Therapeutic lipid-coated hybrid nanoparticles against bacterial infections.RSC advances · 2020Review
- CD46 facilitates entry and dissemination of human cytomegalovirus.Nature communications · 2019Article
- A nanoparticle-based approach to improve the outcome of cancer active immunotherapy with lipopolysaccharides.Drug delivery · 2018Article
- Generation of Well-Defined Micro/Nanoparticles via Advanced Manufacturing Techniques for Therapeutic Delivery.Materials (Basel, Switzerland) · 2018Review
- Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.Molecular pharmaceutics · 2016Article
- Nano- and micro-based systems for immunotolerance induction in multiple sclerosis.Human vaccines & immunotherapeutics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Particle replication in non-wetting templates (PRINT) is a novel nanoparticle platform that provides compositional flexibility with the ability to specify size and shape in formulating vaccines. The PRINT platform also offers manufacturing and cost advantages over traditional particle technologies. Across multiple antigen and adjuvant formulations, robust antibody and cellular responses have been achieved using PRINT particles in mouse models. Preclinical studies applying PRINT technology in the disease areas of influenza, malaria, and pneumonia are described in this commentary. The proof of principle studies pave the way toward significant cost-effective solutions to global vaccine supply needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.